Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 6:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Recurrent C. Difficile Infection
Interventions
CP101, Placebo
Biological · Other
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
61
States / cities
Phoenix, Arizona • Mission Hills, California • Oakland, California + 51 more
Conditions
Clostridium Difficile Infection Recurrence
Interventions
Full Spectrum Microbiota, Placebo
Drug
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
54
States / cities
Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 48 more
Conditions
Clostridium Difficile Infection
Interventions
Oral Vancomycin, Placebo
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, New York
Conditions
Clostridium Difficile Infection
Interventions
Fecal Microbiota Therapy (FMT), Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Terminated Phase 2 Interventional Results available

The Clostridioides Difficile Trial of REC-3964

NCT06536465
Conditions
Recurrent Clostridioides Difficile Infection
Interventions
REC-3964
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 115 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Toms River, New Jersey • San Antonio, Texas
Completed Phase 1Phase 2 Interventional Results available

The ICON Study: Outcomes After FMT for Patients With IBD and CDI

NCT03106844
Conditions
Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions
Fecal Microbiota Transplantation
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Interventions
Oral Vancomycin, Placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Tampa, Florida
Conditions
Clostridium Difficile Infection Recurrence
Interventions
RBX2660
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more
Conditions
Clostridium Difficile
Interventions
Fecal Microbiota Preparation
Drug
Lead sponsor
Microbiome Health Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Naperville, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 1 more
Conditions
Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Fecal Microbiota Transplantation
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile, Clostridioides Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile, CDI
Interventions
VE303, Placebo
Drug
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
29
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Canoga Park, California + 22 more
Conditions
Clostridium Difficile Colitis
Interventions
Standard Vancomycin, Extended Vancomycin
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Royal Oak, Michigan
Conditions
Recurrent C. Difficile Infection
Interventions
Low fecal microbiota dose, Mid fecal microbiota dose, High fecal microbiota dose
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Clostridium Difficile Infection Recurrence
Interventions
Bacillus velezensis DSM 33864, Placebo
Dietary Supplement
Lead sponsor
Novozymes A/S
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Royal Oak, Michigan
Conditions
Clostridium Difficile Infection
Interventions
Vancomycin, fruit juice/placebo
Drug · Dietary Supplement
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Grand Rapids, Michigan
Conditions
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
Interventions
VE303, Placebo
Biological
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Conditions
Recurrent Clostridium Difficile Infection
Interventions
RBX2660 (microbiota suspension)
Biological
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more
Conditions
Clostridioides Difficile Infection
Interventions
AZD5148, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
43
States / cities
Phoenix, Arizona • Chula Vista, California • Sacramento, California + 39 more
Terminated Phase 4 Interventional Results available

Optimal Treatment for Recurrent Clostridium Difficile

NCT02667418
Conditions
Clostridium, Difficile, Fidaxomicin, Vancomycin
Interventions
Fidaxomicin, Vancomycin with Taper/Pulse, Vancomycin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more
Conditions
Clostridium Difficile Infection
Interventions
SER-262, Placebo
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Athens, Alabama • Fountain Valley, California • La Mesa, California + 19 more
Conditions
Clostridium Difficile
Interventions
Misoprostol 100Mcg Tab, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
St Louis, Missouri • Chapel Hill, North Carolina • Nashville, Tennessee
Conditions
Clostridioides Difficile Infection Recurrence
Interventions
Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment.
Other
Lead sponsor
Bactolife A/S
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Atlanta, Georgia • Royal Oak, Michigan • Rochester, Minnesota + 1 more
Conditions
Clostridium Difficile Infection Recurrence
Interventions
FMT oral capsule, Oral Vancomycin, FMT oral placebo, Oral Vancomycin placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Conditions
Clostridioides Difficile Infection
Interventions
LMN-201, Placebo
Drug
Lead sponsor
Lumen Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Escondido, California • Hamden, Connecticut • Tampa, Florida + 12 more